@ARTICLE{10.3389/fendo.2018.00584, AUTHOR={Paternoster, Silvano and Falasca, Marco}, TITLE={Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1}, JOURNAL={Frontiers in Endocrinology}, VOLUME={9}, YEAR={2018}, URL={https://www.frontiersin.org/articles/10.3389/fendo.2018.00584}, DOI={10.3389/fendo.2018.00584}, ISSN={1664-2392}, ABSTRACT={An aging world population exposed to a sedentary life style is currently plagued by chronic metabolic diseases, such as type-2 diabetes, that are spreading worldwide at an unprecedented rate. One of the most promising pharmacological approaches for the management of type 2 diabetes takes advantage of the peptide hormone glucagon-like peptide-1 (GLP-1) under the form of protease resistant mimetics, and DPP-IV inhibitors. Despite the improved quality of life, long-term treatments with these new classes of drugs are riddled with serious and life-threatening side-effects, with no overall cure of the disease. New evidence is shedding more light over the complex physiology of GLP-1 in health and metabolic diseases. Herein, we discuss the most recent advancements in the biology of gut receptors known to induce the secretion of GLP-1, to bridge the multiple gaps into our understanding of its physiology and pathology.} }